RPS6KA5

Across TCGA pan-cancer cohorts, RPS6KA5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPS6KA5 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RPS6KA5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated RPS6KA5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KICH, and PCPG are the cancer types where RPS6KA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.933	0.618	.017	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PCPG	DFS	Median	All	0.070	0.936	<.001	6	view →
BLCA	DFS	Median	All	0.391	0.619	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPS6KA5–UCEC (DFS)

Open the UCEC breakdown →